JHOP - March 2018 Vol 8, No 1
A 20-year-old part of legislation, Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA), represents the primary regulatory structure for how drug manufacturers can distribute and use pharmacoeconomic information in the promotion of their drugs.
- Lynparza First Treatment Approved for Patients with Germline BRCA-Positive Metastatic Breast Cancer
- Gilotrif Receives New Indication as First-Line Treatment for Metastatic NSCLC with Nonresistant EGFR Mutations
- Lutathera First Radioactive Drug Approved for Adults with Gastroenteropancreatic Neuroendocrine Tumors
- Zytiga Receives New Indication, with Prednisone, for Metastatic, High-Risk Castration-Sensitive Prostate Cancer
- Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer
- Imfinzi First Treatment Approved to Reduce Disease Progression in Unresectable Stage III NSCLC After Chemoradiation
In a retrospective cohort analysis of the largest series of patients with mantle-cell lymphoma (MCL) in which real-world economic burden data have been reported, the substantial economic burden of MCL was quantified, with inpatient admissions and office visits as the largest drivers of total costs for patients treated with rituximab, cyclophosphamide, doxorubicin, and vincristine; bendamustine and rituximab; and rituximab, and prescription drug costs as the largest component of total costs for patients receiving ibrutinib.
Results 1 - 10 of 15